Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
Stocks in this Quantisnow insightHealth Care
Historical context for LYEL
Across the 21 sessions after earlier LYEL headlines, the stock closed higher 12 times and lower 9 times, with a median move of 3.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | LYEL | SPY |
|---|---|---|---|
| Aug 7, 2026 | Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 | +3.5% | +0.6% |
| Aug 6, 2026 | Stifel initiated coverage on Lyell Immunopharma with a new price target | +5.7% | -0.2% |
| Jul 22, 2026 | B. Riley Securities initiated coverage on Lyell Immunopharma with a new price target | -2.1% | -0.1% |
| Jun 25, 2026 | Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference | -3.9% | +0.1% |
| Jun 12, 2026 | Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress | -1.6% | +0.5% |
| Jun 8, 2026 | Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion | +2.8% | +0.2% |
Keep researching LYEL
Quantisnow market dataNASDAQ
LYEL
Lyell Immunopharma Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for LYEL
Full LYEL profile on Quantisnow Follow LYEL and get a push notification the moment its next story breaks.